HLX-51

N/A

Report date: 2023/12/08 14:00:08

Base Information

Drug NameHLX-51
Drug Alias NameHLX-51
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 agonists
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsSolid tumoursLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Henlius Biologics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Henlius Biologics Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A